Another NASH delay for Intercept frustrates investors, shares wilt
A previous FDA advisory committee delay for Intercept’s NASH drug may have dampened spirits, but investors perked up after French rival Genfit recently failed to best a placebo with its offering in a keenly anticipated pivotal study. In yet another twist on Friday, the New York drugmaker said the FDA is postponing its adcom again to accommodate the review of additional data it has asked the company to furnish.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.